Condition: Pediatric Cancer · Sponsor: University of California, San Diego
COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel implementation factors that can inform real-world setting implementation. This study will test the impact of COMPRENDO, a peer-navigation intervention, vs. usual care on accrual to childhood cancer therapeutic clinical trials and parental informed consent outcomes. COMPRENDO will be delivered by trained peer navigators in 4 visits. A mixed methods (surveys, individual interviews) implementation evaluation will examine implementation factors that can inform the use of peer navigation in clinical practice, integrating data from clinicians, navigators, administrators, and parents pre and post the RCT.
This description comes directly from the study's public registry record.
M.Paula Aristizabal, MD, MAS · 858-966-5811 · paristizabal@rchsd.org
Always discuss trial participation with your own doctor first.
| Children's of Alabama/University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Rady Children's Hospital San Diego/University of California San Diego Moores Cancer Center | San Diego, California, United States | Recruiting |
| University of California San Francisco Benioff Children's Hospitals | San Francisco, California, United States | Recruiting |
| Dana Farber Cancer Institute/Boston Children's Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06055296